Fortrea Holdings Inc. (FTRE): Cash & Equivalents

Annual figures by period end, from SEC filings.

$174.60M
As of 2025-12-31
$168.60M
As of 2026-06-30
+16.0%
3-year compound annual growth
2022-12-31: $112.00M2023-12-31: $108.60M2024-12-31: $118.50M2025-12-31: $174.60M$174.60M
2022-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$174.60M+47.3%2026-02-26, Balance as of period end
2024-12-31$118.50M+9.1%2026-02-26, Balance as of period end
2023-12-31$108.60M-3.0%2025-03-03, Balance as of period end
2022-12-31$112.00Mn/a2024-03-13, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Fortrea Holdings Inc. (FTRE)2025-12-31$174.60M+47.3%
RadNet, Inc. (RDNT)2025-12-31$767.22M+3.7%
Guardant Health, Inc. (GH)2025-12-31$378.20M-28.0%
Caris Life Sciences, Inc. (CAI)2025-12-31$796.27Mn/m
Quest Diagnostics Inc (DGX)2025-12-31$420.00M-23.5%
Labcorp Holdings Inc. (LH)2025-12-31$532.30M-65.0%
Veracyte, Inc. (VCYT)2025-12-31$362.58M+51.7%
CareDx, Inc. (CDNA)2025-12-31$65.43M-43.0%
Castle Biosciences Inc (CSTL)2025-12-31$116.73M-2.5%

Compare FTRE, RDNT, GH, CAI side by side · Screen every company in Services-Medical Laboratories ↗